2020
DOI: 10.33667/2078-5631-2020-30-37-41
|View full text |Cite
|
Sign up to set email alerts
|

Drug for contrast-enhanced ultrasound examination: new dimension in early diagnosis of angionephrosclerosis in patients with type 2 diabetes on non-alcoholic fatty liver disease background

Abstract: Objective. To evaluate the diagnostic efficiency of the contrast-enhanced third-generation agent in the detection of angionephrosclerosis in patients with type 2 diabetes and non-alcoholic fatty liver disease background.Materials and methods. 26 patients (9 men and 17 women; mean age 61.5 ± 4.3 years) with a confirmed diagnosis of type 2 diabetes mellitus and NAFLD were examined. All patients underwent complex diagnostics, including: quantitative ultrasound steatometry of the liver in the framework of combined… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 6 publications
0
0
0
Order By: Relevance